Compare NetEase Inc (NTES) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
NetEase Inc vs Revvity Inc — how do they compare? NetEase Inc trades at $124.24 (market cap $76.09B), while Revvity Inc trades at $154.18 (market cap $16.98B). The key difference: NetEase Inc is far larger — about 4.5× Revvity Inc's market cap, and NetEase Inc pays the higher dividend (2.45%). Which is the better fit depends on your goals — on Pluang, investors hold NetEase Inc for 73 Days and Revvity Inc for 12 Days on average.
| NTES | RVTY | |
|---|---|---|
Market Cap | $76.09B | $16.98B |
Volume | 486,447 | 1,456,900 |
Sector | Technology | Health |
52-Week High | $152.85 | $157.36 |
52-Week Low | $109.26 | $82.26 |
Typical Hold Time | 73 Days | 12 Days |
Enterprise Value | $51.81B | $19.30B |
Dividend Yield | 2.45% | 0.18% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NetEase (NTES) trades at $119.60, down 0.84% with neutral technical signals. The company maintains strong fundamentals with $112.63B revenue and 27.88% net margin in 2025, though recent quarterly earnings show mixed results with two misses and one beat. Analyst consensus remains strongly bullish with 82% buy ratings and $168 price target, representing 40% upside potential from current levels.
NTES presents compelling value with reasonable P/E of 15.9 and strong cash flow generation, but faces execution risks from inconsistent earnings performance and competitive pressures in gaming. The stock's current valuation discount to analyst targets offers opportunity, though investors should monitor Q3 2026 results for sustained growth trajectory.
RVTY trades at $152.16, down 0.94% on the day, but maintains a bullish technical trend with strong moving average signals and support near $149. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results expected soon. Revenue remains stable around $2.9 billion, though net income margins have softened slightly. Recent news highlights product launches and strategic acquisitions, such as the Human Cell Design deal, to bolster its life sciences portfolio.
The outlook is supported by analyst optimism with a 51.72% buy rating and a consensus price target of $132.13, though the current price trades above this target. Key risks include premium valuation metrics, margin pressures, and exposure to macroeconomic headwinds. The stock's proximity to its 52-week high suggests momentum but warrants caution given rich multiples.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About NetEase Inc
NetEase, which started on an internet portal service in 1997, is a leading online services provider in China. Its key services include online/mobile games, cloud music, media, advertising, email, live streaming, online education, and e-commerce. The company develops and operates some of the China's most popular PC client and mobile games, and it partners with global leading game developers, such as Blizzard Entertainment and Mojang (a Microsoft subsidiary).
Read more on NTES →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
